Rua Life Sciences PLC
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast… Read more
Rua Life Sciences PLC (RUA) - Net Assets
Latest net assets as of September 2025: GBX7.18 Million GBX
Based on the latest financial reports, Rua Life Sciences PLC (RUA) has net assets worth GBX7.18 Million GBX as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX9.12 Million) and total liabilities (GBX1.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX7.18 Million |
| % of Total Assets | 78.81% |
| Annual Growth Rate | 10.55% |
| 5-Year Change | -13.1% |
| 10-Year Change | 505.27% |
| Growth Volatility | 306.84 |
Rua Life Sciences PLC - Net Assets Trend (1994–2025)
This chart illustrates how Rua Life Sciences PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rua Life Sciences PLC (1994–2025)
The table below shows the annual net assets of Rua Life Sciences PLC from 1994 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | GBX7.39 Million | +2.92% |
| 2024-03-31 | GBX7.18 Million | +53.36% |
| 2023-03-31 | GBX4.68 Million | -28.87% |
| 2022-03-31 | GBX6.58 Million | -22.60% |
| 2021-03-31 | GBX8.51 Million | +273.89% |
| 2020-03-31 | GBX2.27 Million | -24.17% |
| 2019-03-31 | GBX3.00 Million | +195.28% |
| 2018-03-31 | GBX1.02 Million | -3.41% |
| 2017-03-31 | GBX1.05 Million | -13.87% |
| 2016-03-31 | GBX1.22 Million | -24.34% |
| 2015-03-31 | GBX1.61 Million | -2.20% |
| 2014-03-31 | GBX1.65 Million | -39.00% |
| 2013-03-31 | GBX2.71 Million | -14.86% |
| 2012-03-31 | GBX3.18 Million | +1.79% |
| 2011-03-31 | GBX3.12 Million | -42.32% |
| 2010-03-31 | GBX5.41 Million | -11.73% |
| 2009-03-31 | GBX6.13 Million | -13.80% |
| 2008-03-31 | GBX7.11 Million | +140.26% |
| 2007-03-31 | GBX2.96 Million | -42.03% |
| 2006-03-31 | GBX5.11 Million | -9.64% |
| 2005-03-31 | GBX5.65 Million | -25.29% |
| 2004-03-31 | GBX7.57 Million | +9.54% |
| 2003-03-31 | GBX6.91 Million | -85.05% |
| 2002-03-31 | GBX46.21 Million | +28.49% |
| 2001-03-31 | GBX35.96 Million | -13.45% |
| 2000-03-31 | GBX41.55 Million | +911.24% |
| 1999-03-31 | GBX4.11 Million | +62.86% |
| 1998-03-31 | GBX2.52 Million | -19.08% |
| 1997-03-31 | GBX3.12 Million | +359.88% |
| 1996-03-31 | GBX678.00K | +1440.91% |
| 1995-03-31 | GBX44.00K | -86.67% |
| 1994-03-31 | GBX330.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rua Life Sciences PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6154.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX3.10 Million | 42.52% |
| Other Comprehensive Income | GBX10.46 Million | 143.40% |
| Other Components | GBX13.71 Million | 187.85% |
| Total Equity | GBX7.30 Million | 100.00% |
Rua Life Sciences PLC Competitors by Market Cap
The table below lists competitors of Rua Life Sciences PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TRULY INTL HLDGS
MU:TYU2
|
$1.01K |
|
PERUSAHAAN GAS -B-
MU:PGB1
|
$1.01K |
|
Raya Holding For Financial Investments
EGX:RAYA
|
$1.01K |
|
European Green Transition PLC
LSE:EGT
|
$1.01K |
|
European Opportunities Trust plc
LSE:EOT
|
$1.01K |
|
DMK Pharmaceuticals Corporation
PINK:DMKPQ
|
$1.01K |
|
Ces Synergies Inc
PINK:CESX
|
$1.01K |
|
Caerus Mineral Resources PLC
LSE:CMRS
|
$1.01K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rua Life Sciences PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,182,000 to 7,298,000, a change of 116,000 (1.6%).
- Net income of 1,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 110,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX1.00K | +0.01% |
| Other Comprehensive Income | GBX110.00K | +1.51% |
| Other Changes | GBX5.00K | +0.07% |
| Total Change | GBX- | 1.62% |
Book Value vs Market Value Analysis
This analysis compares Rua Life Sciences PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 121.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 61.74x to 121.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-03-31 | GBX0.23 | GBX14.25 | x |
| 1995-03-31 | GBX0.03 | GBX14.25 | x |
| 1996-03-31 | GBX0.47 | GBX14.25 | x |
| 1997-03-31 | GBX2.13 | GBX14.25 | x |
| 1998-03-31 | GBX1.40 | GBX14.25 | x |
| 1999-03-31 | GBX1.99 | GBX14.25 | x |
| 2000-03-31 | GBX17.44 | GBX14.25 | x |
| 2001-03-31 | GBX11.51 | GBX14.25 | x |
| 2002-03-31 | GBX12.38 | GBX14.25 | x |
| 2003-03-31 | GBX1.80 | GBX14.25 | x |
| 2004-03-31 | GBX1.98 | GBX14.25 | x |
| 2005-03-31 | GBX1.48 | GBX14.25 | x |
| 2006-03-31 | GBX1.33 | GBX14.25 | x |
| 2007-03-31 | GBX0.77 | GBX14.25 | x |
| 2008-03-31 | GBX1.58 | GBX14.25 | x |
| 2009-03-31 | GBX1.26 | GBX14.25 | x |
| 2010-03-31 | GBX1.11 | GBX14.25 | x |
| 2011-03-31 | GBX0.64 | GBX14.25 | x |
| 2012-03-31 | GBX0.65 | GBX14.25 | x |
| 2013-03-31 | GBX0.56 | GBX14.25 | x |
| 2014-03-31 | GBX0.34 | GBX14.25 | x |
| 2015-03-31 | GBX0.33 | GBX14.25 | x |
| 2016-03-31 | GBX0.24 | GBX14.25 | x |
| 2017-03-31 | GBX0.19 | GBX14.25 | x |
| 2018-03-31 | GBX0.18 | GBX14.25 | x |
| 2019-03-31 | GBX0.23 | GBX14.25 | x |
| 2020-03-31 | GBX0.15 | GBX14.25 | x |
| 2021-03-31 | GBX0.48 | GBX14.25 | x |
| 2022-03-31 | GBX0.30 | GBX14.25 | x |
| 2023-03-31 | GBX0.21 | GBX14.25 | x |
| 2024-03-31 | GBX0.21 | GBX14.25 | x |
| 2025-03-31 | GBX0.12 | GBX14.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rua Life Sciences PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.02%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.27x
- Recent ROE (0.01%) is above the historical average (-57.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 105.45% | 36.02% | 0.46x | 6.30x | GBX315.00K |
| 1995 | -647.73% | -29.75% | 0.49x | 44.18x | GBX-289.40K |
| 1996 | -53.39% | -20.70% | 0.85x | 3.04x | GBX-429.80K |
| 1997 | -36.34% | -52.14% | 0.47x | 1.50x | GBX-1.44 Million |
| 1998 | -23.54% | -32.98% | 0.46x | 1.55x | GBX-846.30K |
| 1999 | -24.36% | -36.02% | 0.51x | 1.32x | GBX-1.41 Million |
| 2000 | -4.25% | -51.10% | 0.08x | 1.07x | GBX-5.92 Million |
| 2001 | -17.31% | -168.20% | 0.10x | 1.07x | GBX-9.82 Million |
| 2002 | -27.88% | -278.45% | 0.09x | 1.06x | GBX-17.50 Million |
| 2003 | -569.75% | -2854.10% | 0.15x | 1.34x | GBX-40.05 Million |
| 2004 | 6.98% | 146.67% | 0.04x | 1.06x | GBX-228.70K |
| 2005 | -33.03% | -1362.77% | 0.02x | 1.06x | GBX-2.43 Million |
| 2006 | -10.24% | -36.70% | 0.25x | 1.13x | GBX-1.03 Million |
| 2007 | -71.63% | -768.48% | 0.08x | 1.24x | GBX-2.42 Million |
| 2008 | -16.29% | -78.10% | 0.19x | 1.10x | GBX-1.87 Million |
| 2009 | -20.37% | -99.21% | 0.19x | 1.10x | GBX-1.86 Million |
| 2010 | -35.53% | -141.19% | 0.23x | 1.12x | GBX-2.46 Million |
| 2011 | -80.11% | -159.30% | 0.42x | 1.21x | GBX-2.81 Million |
| 2012 | 1.12% | 1.13% | 0.88x | 1.12x | GBX-282.20K |
| 2013 | -20.60% | -22.32% | 0.82x | 1.13x | GBX-828.03K |
| 2014 | -29.92% | -196.42% | 0.13x | 1.18x | GBX-658.80K |
| 2015 | -13.59% | -38.04% | 0.32x | 1.10x | GBX-380.84K |
| 2016 | -34.34% | -67.04% | 0.47x | 1.09x | GBX-541.48K |
| 2017 | -17.98% | -38.60% | 0.43x | 1.08x | GBX-294.34K |
| 2018 | -3.35% | -8.42% | 0.37x | 1.07x | GBX-135.60K |
| 2019 | -20.30% | -131.53% | 0.15x | 1.03x | GBX-909.00K |
| 2020 | -35.87% | -166.87% | 0.20x | 1.10x | GBX-1.04 Million |
| 2021 | -17.06% | -94.96% | 0.15x | 1.19x | GBX-2.30 Million |
| 2022 | -31.39% | -127.20% | 0.21x | 1.16x | GBX-2.73 Million |
| 2023 | -42.77% | -91.92% | 0.38x | 1.21x | GBX-2.47 Million |
| 2024 | -20.05% | -65.72% | 0.27x | 1.14x | GBX-2.16 Million |
| 2025 | 0.01% | 0.02% | 0.44x | 1.27x | GBX-728.80K |
Industry Comparison
This section compares Rua Life Sciences PLC's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $78,259,050
- Average return on equity (ROE) among peers: -35.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rua Life Sciences PLC (RUA) | GBX7.18 Million | 105.45% | 0.27x | $1.01K |
| AOTI Inc (AOTI) | $3.41 Million | 51.02% | 1.74x | $5.95K |
| Belluscura Plc (BELL) | $1.20 Million | -81.38% | 0.34x | $366.21 |
| Creo Medical Group PLC (CREO) | $59.80 Million | -36.29% | 0.28x | $8.34K |
| Inspiration Healthcare Group PLC (IHC) | $28.97 Million | -20.83% | 0.69x | $2.87K |
| Intelligent Ultrasound Group PLC (IUG) | $12.16 Million | -24.53% | 0.32x | $5.19K |
| NIOX Group PLC (NIOX) | $440.90 Million | -11.32% | 0.11x | $31.53K |
| Surgical Innovations Group plc (SUN) | $1.37 Million | -123.23% | 1.08x | $510.74 |